Castle biosciences stock.

Europe PMC is an archive of life sciences journal literature.The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days.What exchange does Castle Biosciences trade on and what is the company’s stock symbol? Castle Biosciences’ stock is traded on The Nasdaq Global Market under the ticker symbol "CSTL". The estimated Net Worth of Mara G. Aspinall is at least $2.42 Million dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over $1,626,983 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences.Health has made over 7 trades of the Castle Biosciences stock since 2019, according to the Form 4 filled with the SEC. Most recently Health sold 250,000 units of CSTL stock worth $8,625,000 on 12 May 2020.

The estimated net worth of Daniel Bradbury is at least $1.27 million as of November 20th, 2023. Mr. Bradbury owns 63,885 shares of Castle Biosciences stock worth more than $1,270,034 as of November 24th. This net worth evaluation does not reflect any other assets that Mr. Bradbury may own. Learn More about Daniel Bradbury's net worth.Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating …

Castle Biosciences had a GAAP loss of 70 cents a share, approximately 20 cents a share above expectations. Revenues rose 44% on a year-to-year basis to $50.1 million, almost $6 million over the ...Castle Biosciences has risen higher in 1 of those 4 years over the subsequent 52-week period, corresponding to a historical accuracy of 25%. Is Castle Biosciences Stock Undervalued? The current Castle Biosciences [ CSTL] share price is $19.99. The Score for CSTL is 73, which is 46% above its historic median score of 50, and infers lower risk ...

Innovators With A Proven Track Record of Success. An experienced team with deep expertise in discovering, developing, and commercializing diagnostic and prognostic tests. Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes.Biosciences; Research Funding - Castle Biosciences. CPG: Other Remuneration - Indiana University. DM: President and CEO - Castle Biosciences; Stock Ownership - Castle Biosciences. KMO: Director of ...11/08/2023 - 01:00 PM. FRIENDSWOOD, Texas -- (BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the following investor conferences later this …Under the terms of the definitive agreement, AltheaDx will become a wholly owned subsidiary of Castle Biosciences. At closing, Castle will pay $65.0 million in initial consideration to AltheaDx ...Europe PMC is an archive of life sciences journal literature.

CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 77-0701774 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) ... registrant’s common stock on June 30, 2020, as reported by the Nasdaq Global Market. As of March 5, 2021, there were 24,978,424 shares of …

Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.

3 Haz 2023 ... The company's shares closed yesterday at $22.73. Souda covers the Healthcare sector, focusing on stocks such as Guardant Health, Repligen, and ...Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes.Castle Biosciences is forecast to grow earnings and revenue by 32.8% and 14.8% per annum respectively. EPS is expected to grow by 32.1% per annum. Return on equity is forecast to be -26.8% in 3 years.A stay in one of the world’s most beautiful castle hotels is truly a once-in-a-lifetime experience. These days, you don’t have to be born a royal to live like one, which is why we’ve rounded up some of the best castles in the world that you...Nov 23, 2023 · Castle Biosciences Inc’s trailing 12-month revenue is $192.0 million with a -39.3% profit margin. Year-over-year quarterly sales growth most recently was 66.2%. Analysts expect adjusted earnings to reach $-2.723 per share for the current fiscal year. Castle Biosciences Inc does not currently pay a dividend. Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently up 6.59% so far this month. During the month of November, Castle Biosciences Inc’s stock price has reached a high of $17.08 and a low of $15.28. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to date ...Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating …

6 hours ago · Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx-Melanoma in patients diagnosed with cutaneous melanoma. Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new discovery data from an ongoing study exploring the potential for developing a complementary, minimally invasive test to evaluate small, suspicious lesions of uncertain malignant potential in patients’ eyes.The 31-GEP test (DecisionDx-Melanoma; Castle Biosciences Inc, Friendswood, TX) was used to analyze the expression of 27 prognostic genes (28 probes) and three control genes from primary CM tumors, as previously described. 21 All 31-GEP testing was performed in a College of American Pathologists–accredited and Clinical Laboratory Improvement ...Castle Biosciences announced that it has completed its acquisition of AltheaDx, Inc. ... up to an additional $75.0 million in cash and common stock will be payable in connection with the ...52.55K (21.02% of Avg) 65 Day Avg: 250.03K Becton Dickinson & Co. Siemens Healthineers AG Qiagen N.V. Company & People Research & Ratings President, Chief Executive Officer & Director Franklin...

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx®-Melanoma in patients …Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication …

The latest Castle Biosciences stock prices, stock quotes, news, and CSTL history to help you invest and trade smarter. 559.98%. Get the latest Castle Biosciences Inc (CSTL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...AltheaDx filed for an initial public stock offering in December 2014 but shelved the proposed stock sale in early 2015. Castle Biosciences, which went public in 2019, makes tests that help guide ...Castle Biosciences stock opened at $19.97 on Monday. The firm has a market capitalization of $537.39 million, a P/E ratio of -7.03 and a beta of 0.97. The company has a 50-day simple moving ...David Kabakoff CSTL stock SEC Form 4 insiders trading. David has made over 21 trades of the Castle Biosciences stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 30,000 units of CSTL stock worth $2,252,100 on 17 June 2021.. The largest trade he's ever made was selling 250,000 units of Castle …These 4 analysts have an average price target of $38.75 versus the current price of Castle Biosciences at $22.02, implying upside. Below is a summary of how these 4 analysts rated Castle ...Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.47 per share a year ago.

Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently down 7.52% so far this month. During the month of October, Castle Biosciences Inc’s stock price has reached a high of $16.84 and a low of $12.07. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to ...

Castle Biosciences (NASDAQ:CSTL) has a recorded net income of -$67.14 million. CSTL has generated -$2.84 earnings per share over the last four quarters. What is Castle Biosciences's EPS forecast for next year? Castle Biosciences's earnings are expected to grow from ($3.15) per share to ($3.00) per share in the next year.

In a report released on July 7, Puneet Souda from SVB Securities maintained a Buy rating on Castle Biosciences (CSTL – Research Report).The company’s shares closed last Friday at $20.30 ...Castle Biosciences Inc’s Stock Price as of Market Close. As of October 25, 2023, 4:00 PM, CST, Castle Biosciences Inc’s stock price was $12.66. Castle Biosciences Inc is down 4.24% from its previous closing price of $13.22. During the last market session, Castle Biosciences Inc’s stock traded between $12.78 and $13.25. …The primary residents of European castles during the Middle Ages were the lord and lady of the realm. These might be royalty or simply the liege lords of the district where the castle was built.Jun 6, 2023 · Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently down 39.75% so far this month. During the month of June, Castle Biosciences Inc’s stock price has reached a high of $24.55 and a low of $9.26. Over the last year, Castle Biosciences Inc has hit prices as high as $36.10 and as low as $9.26. Year to date ... Shares of Castle Biosciences ( CSTL 0.15%) closed this week down 12.6% for the week, after being down as much as 18.3% for the week, according to data provided by S&P Global Market Intelligence ...Castle Biosciences Inc Stock Earnings The value each CSTL share was expected to gain vs. the value that each CSTL share actually gained. CSTL ( CSTL ) reported Q3 2023 earnings per share (EPS) of -$0.26 , beating estimates of -$0.76 by 66.32% .2,091.70 +34.50(+1.68%) Castle Biosciences, Inc. (CSTL) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.97 -0.02 (-0.10%) At close: 04:00PM EST 20.35 +0.38 (+1.90%)...What is the target price for Castle Biosciences (CSTL) stock? The latest price target for Castle Biosciences ( NASDAQ: CSTL) was reported by Keybanc on Friday, August 4, 2023. The analyst firm set ...AltheaDx filed for an initial public stock offering in December 2014 but shelved the proposed stock sale in early 2015. Castle Biosciences, which went public in 2019, makes tests that help guide ...Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe …Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will highlight the impactful risk stratification provided by its TissueCypher test in patients with Barrett's esophagus (BE) through two posters at the 2023 American College of Gastroenterology (ACG 2023) Annual Scientific Meeting, taking place Oct. 20-25, in Vancouver ...

thefly.com — Castle Biosciences raises FY23 revenue view to at least $200M, consensus $187.1M News • Nov 1, 2023 GamesIndustry.biz — Remedy posts flat revenue for Q3 2023Stock analysis for Castle Biosciences Inc (CSTL:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Castle Biosciences announced that it has completed its acquisition of AltheaDx, Inc. ... up to an additional $75.0 million in cash and common stock will be payable in connection with the ...Instagram:https://instagram. fha mortgage providerssox etfrobinhood shiba inuprop firms futures Jun 5, 2023 · Shares of Castle Biosciences ( CSTL 2.42%) were down more than 47% on Monday afternoon as three analysts lowered their price targets for the medical diagnostic stock. The healthcare stock is down ... ford ex dividend dateschwab purchased money funds Mar 1, 2023 · Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.25 per share a year ago. splv etf Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will highlight the impactful risk stratification provided by its TissueCypher test in patients with Barrett's esophagus (BE) through two posters at the 2023 American College of Gastroenterology (ACG 2023) Annual Scientific Meeting, taking place Oct. 20-25, in Vancouver ...4 Wall Street research analysts have issued 1-year price targets for Castle Biosciences' shares. Their CSTL share price targets range from $25.00 to $41.00. On average, they anticipate the company's stock price to reach $32.29 in the next twelve months. This suggests a possible upside of 64.4% from the stock's current price.